ACRP CCRC Exam Practice 2025 | COMPLETE 150+ Question
Bank | Complete Study Guide | Verified Questions & Answers
| Latest Updated Version | Exam Prep | 100% Pass Success
Resource | Instant Download PDF
1. A clinical trial is designed to compare two treatments where neither the investigator nor the subject
knows which treatment is being administered. This design is best described as:
A) Open-label
B) Single-blind
C) Double-blind
D) Crossover
Answer: C) Double-blind
Rationale: In a double-blind study, both the investigator and the subject are blinded to treatment
assignment to minimize bias. This design characteristic is a fundamental element of study design that
CCRCs must understand.
2. The primary purpose of a protocol is to:
A) Secure funding for the clinical trial
B) Describe the objectives, methodology, and conduct of the study
C) Document adverse events
D) Obtain regulatory approval
Answer: B) Describe the objectives, methodology, and conduct of the study
Rationale: The protocol is the essential document that defines all aspects of study conduct including
objectives, design, methodology, statistical considerations, and organization. CCRCs must understand
elements of a protocol to ensure compliance.
3. An Investigational Brochure (IB) contains all of the following EXCEPT:
A) Summary of nonclinical studies
B) Summary of clinical studies
,C) Site staff training records
D) Description of adverse events and risks
Answer: C) Site staff training records
Rationale: The IB provides investigators with information on the investigational product's pharmacology,
toxicology, pharmacokinetics, and clinical experience. Training records are maintained at the site, not in
the IB.
4. A study with a crossover design allows subjects to:
A) Receive only the active treatment
B) Receive both the active treatment and placebo at different periods
C) Choose their treatment assignment
D) Withdraw at any time without reason
Answer: B) Receive both the active treatment and placebo at different periods
Rationale: In a crossover design, each subject serves as their own control by receiving both treatments
in sequence. This design characteristic is part of the scientific concepts CCRCs must understand.
5. The term "screen fail rate" refers to:
A) The number of subjects who withdraw due to adverse events
B) The percentage of subjects screened who are not enrolled
C) The number of monitors who fail to visit
D) The percentage of sites that fail to enroll
Answer: B) The percentage of subjects screened who are not enrolled
Rationale: Screen fail rate is a statistical principle related to study design that impacts sample size
calculations and recruitment planning. CCRCs need to understand this concept for feasibility
assessments.
6. Which of the following is a study endpoint?
,A) The number of sites participating
B) The primary outcome measure used to assess treatment effect
C) The budget allocation
D) The date of protocol approval
Answer: B) The primary outcome measure used to assess treatment effect
Rationale: Endpoints are specific measurements used to evaluate the study objectives and treatment
effects. They are fundamental elements of protocol design.
7. Randomization in a clinical trial is primarily used to:
A) Ensure subjects receive the best treatment
B) Reduce bias in treatment assignment
C) Reduce the number of subjects needed
D) Increase the study budget
Answer: B) Reduce bias in treatment assignment
Rationale: Randomization helps ensure treatment groups are comparable and reduces selection bias.
This is a key study design characteristic CCRCs must understand.
8. The rationale for complying with a protocol includes all of the following EXCEPT:
A) Ensuring subject safety
B) Maintaining data integrity
C) Expediting study completion at any cost
D) Meeting regulatory requirements
Answer: C) Expediting study completion at any cost
Rationale: Protocol compliance is essential for subject safety, data integrity, regulatory compliance, and
scientific validity. Expediting at the cost of compliance is never acceptable.
9. An open-label study means:
, A) All subjects receive placebo
B) Both subjects and investigators know the treatment assignment
C) Subjects are blinded but investigators are not
D) The study is conducted in an open setting
Answer: B) Both subjects and investigators know the treatment assignment
Rationale: Open-label means all parties know the treatment assignment. This is a treatment assignment
type that CCRCs must recognize.
10. A comparator product in a clinical trial is used to:
A) Replace the investigational product
B) Provide a standard against which the investigational product is compared
C) Treat adverse events exclusively
D) Increase subject recruitment
Answer: B) Provide a standard against which the investigational product is compared
Rationale: Comparator products (placebo or active) serve as the reference for evaluating the
investigational product's effects. This is part of study design knowledge.
11. The inclusion/exclusion criteria in a protocol are designed to:
A) Make recruitment easier
B) Ensure the study population is appropriate for the research question
C) Exclude all subjects with comorbidities
D) Increase the sample size
Answer: B) Ensure the study population is appropriate for the research question
Rationale: Eligibility requirements define who can participate, ensuring the study population is
appropriate for answering the research question while protecting subject safety.
12. A placebo is defined as:
Bank | Complete Study Guide | Verified Questions & Answers
| Latest Updated Version | Exam Prep | 100% Pass Success
Resource | Instant Download PDF
1. A clinical trial is designed to compare two treatments where neither the investigator nor the subject
knows which treatment is being administered. This design is best described as:
A) Open-label
B) Single-blind
C) Double-blind
D) Crossover
Answer: C) Double-blind
Rationale: In a double-blind study, both the investigator and the subject are blinded to treatment
assignment to minimize bias. This design characteristic is a fundamental element of study design that
CCRCs must understand.
2. The primary purpose of a protocol is to:
A) Secure funding for the clinical trial
B) Describe the objectives, methodology, and conduct of the study
C) Document adverse events
D) Obtain regulatory approval
Answer: B) Describe the objectives, methodology, and conduct of the study
Rationale: The protocol is the essential document that defines all aspects of study conduct including
objectives, design, methodology, statistical considerations, and organization. CCRCs must understand
elements of a protocol to ensure compliance.
3. An Investigational Brochure (IB) contains all of the following EXCEPT:
A) Summary of nonclinical studies
B) Summary of clinical studies
,C) Site staff training records
D) Description of adverse events and risks
Answer: C) Site staff training records
Rationale: The IB provides investigators with information on the investigational product's pharmacology,
toxicology, pharmacokinetics, and clinical experience. Training records are maintained at the site, not in
the IB.
4. A study with a crossover design allows subjects to:
A) Receive only the active treatment
B) Receive both the active treatment and placebo at different periods
C) Choose their treatment assignment
D) Withdraw at any time without reason
Answer: B) Receive both the active treatment and placebo at different periods
Rationale: In a crossover design, each subject serves as their own control by receiving both treatments
in sequence. This design characteristic is part of the scientific concepts CCRCs must understand.
5. The term "screen fail rate" refers to:
A) The number of subjects who withdraw due to adverse events
B) The percentage of subjects screened who are not enrolled
C) The number of monitors who fail to visit
D) The percentage of sites that fail to enroll
Answer: B) The percentage of subjects screened who are not enrolled
Rationale: Screen fail rate is a statistical principle related to study design that impacts sample size
calculations and recruitment planning. CCRCs need to understand this concept for feasibility
assessments.
6. Which of the following is a study endpoint?
,A) The number of sites participating
B) The primary outcome measure used to assess treatment effect
C) The budget allocation
D) The date of protocol approval
Answer: B) The primary outcome measure used to assess treatment effect
Rationale: Endpoints are specific measurements used to evaluate the study objectives and treatment
effects. They are fundamental elements of protocol design.
7. Randomization in a clinical trial is primarily used to:
A) Ensure subjects receive the best treatment
B) Reduce bias in treatment assignment
C) Reduce the number of subjects needed
D) Increase the study budget
Answer: B) Reduce bias in treatment assignment
Rationale: Randomization helps ensure treatment groups are comparable and reduces selection bias.
This is a key study design characteristic CCRCs must understand.
8. The rationale for complying with a protocol includes all of the following EXCEPT:
A) Ensuring subject safety
B) Maintaining data integrity
C) Expediting study completion at any cost
D) Meeting regulatory requirements
Answer: C) Expediting study completion at any cost
Rationale: Protocol compliance is essential for subject safety, data integrity, regulatory compliance, and
scientific validity. Expediting at the cost of compliance is never acceptable.
9. An open-label study means:
, A) All subjects receive placebo
B) Both subjects and investigators know the treatment assignment
C) Subjects are blinded but investigators are not
D) The study is conducted in an open setting
Answer: B) Both subjects and investigators know the treatment assignment
Rationale: Open-label means all parties know the treatment assignment. This is a treatment assignment
type that CCRCs must recognize.
10. A comparator product in a clinical trial is used to:
A) Replace the investigational product
B) Provide a standard against which the investigational product is compared
C) Treat adverse events exclusively
D) Increase subject recruitment
Answer: B) Provide a standard against which the investigational product is compared
Rationale: Comparator products (placebo or active) serve as the reference for evaluating the
investigational product's effects. This is part of study design knowledge.
11. The inclusion/exclusion criteria in a protocol are designed to:
A) Make recruitment easier
B) Ensure the study population is appropriate for the research question
C) Exclude all subjects with comorbidities
D) Increase the sample size
Answer: B) Ensure the study population is appropriate for the research question
Rationale: Eligibility requirements define who can participate, ensuring the study population is
appropriate for answering the research question while protecting subject safety.
12. A placebo is defined as:
